Basic Information
Engeljein was jointly developed by Boehringer Ingelheim and Eli-Lilly and was first approved by the European Medicines Agency (EMA) on May 22, 2014, on August 1, 2014. Approved by the US Food and Drug Administration (FDA), approved by the Japan Pharmaceutical and Medical Device Administration (PMDA) on December 26, 2014, and obtained by the China Food and Drug Administration (CFDA) on September 20, 2017. Approved for listing. It is jointly marketed by Boehringer Ingelheim and Lilly, under the trade name Jardiance®, and is marketed in China under the trade name Ou Tangjing®.
Englitavir is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Combined with exercise and diet as an adjunct to improve glycemic control in adult patients with type 2 diabetes.
Jardiance® is an oral tablet containing 10 mg or 25 mg of enclave per tablet. The recommended starting dose is 10 mg each time, once a day, the maximum dose is 25 mg each time, once a day.
Structural formula
Mechanism
Engliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that blocks the reabsorption of glucose in the kidneys and excretes excess glucose into the body, thereby reducing blood sugar levels. And the hypoglycemic effect is independent of beta cell function and insulin resistance.
Synthetic route
Research key data
This article is reproduced from：https://news.pharmacodia.com/news/html/info/info-detail.html?id=29203
